Regulation FD Disclosure Form 8 K

Item 7.01 Regulation FD Disclosure

On October 15, 2024, representatives of Elanco Animal Health Incorporated (the "Company") presented the abstract titled "Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor" at the International Society for Companion Animal Infectious Diseases (ISCAID) symposium.

The Zenrelia™ (ilunocitinib tablets) study summarized in the abstract was conducted by the Company with sixty-eight approximately 10-month-old Beagle dogs previously vaccinated more than seven months prior to receiving a booster vaccination. The dogs were randomly assigned to three treatment groups stratified by sex and pre-study titer levels: sham dosed (control group) and ilunocitinib at 1X or 3X the label dose. The study concluded that when dogs were administered ilunocitinib for 56 days at 1X or 3X the labeled dose, the number of dogs with protective titers on days 43 and 56 following administration of canine core booster vaccinations, including rabies, were similar among all treated and control groups. No serious adverse events were observed.

A copy of the abstract has been posted on the Company's Investors Relations website under the "Zenrelia Approval Call" event.

Additionally, the Company has received approval for Zenrelia™ in Canada. Further information is available via the Health Canada Drug Product Database website.

The information in this Item 7.01 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.